Product Description
Mechanisms of Action: Adenylosuccinate Synthase Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lung Cancer|Sarcoma|Mesothelioma|Pancreatic Cancer
Phase 1: Brain Stem Cancer|Glioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00075894 |
CDR0000349473 | P1 |
Completed |
Brain Stem Cancer|Glioma |
None |
2019-03-21 |
Treatments |
|
NCT00062283 |
SALMEDIX-SDX-102-01 | P2 |
Completed |
Mesothelioma|Pancreatic Cancer|Lung Cancer|Sarcoma |
2005-12-01 |
2019-03-21 |
Treatments |